Search results for: Competition
Filter search results
Biosimilar Competition: Lessons from Europe and Prospects for the US
14 March 2014, 12:00am
At this OHE Lunchtime Seminar, Professor Henry Grabowski presented the results of his recent research on competition in five European countries on Eprex® (epoetin alpha) and Neupogen® (filigrastim) and their…
OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures
5 June 2019, 11:00pm
…competing products appear; and, a third period when generic competition emerges. Demand in each period depends on how many patients were treated in previous periods. Similarly, payment/pricing rules used will…
Two Economists Join OHE
10 March 2011
…of competition and regulation, and UK and EU competition law. Prior to the OHE, Arik was with the UK Competition Commission, where he was involved in a wide range of cases…
Biosimilar Competition: Lessons from Europe and Prospects for the US
2 December 2014
…to encourage biosimilars, and physicians will become more experienced with them. Download Grabowski, H., 2014. Biosimilars Competition: Lessons from Europe and Prospects for the US. London: Office of Health…
Biosimilars and Data Exclusivity
8 June 2010
…from 12.9 to 16.2 years for biologics, without competition from biosimilars. In estimating the potential effect of biosimilars on breakeven times and incentives for innovation, Prof Grabowski noted that price competition…
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
…and, how to keep competition going to incentivise the development and adoption of new improved versions of such solutions? There is no guarantee that we have a pathway to developing…
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
…include: ‘Exits from Vaccine Markets in the US: The Role of Competition vs. Regulation’ (Danzon and Pereira, 2011); ‘Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances’ (Danzon, Nicholson…
Canberra Hypothesis: the Economics of the Prescription Medicine Market
1 July 1975
The burden of this paper was that it was a fundamental misconception to believe that price competition was lacking in the prescription medicine market, at least in the context of…
Economic Evidence and NHS Reforms in England
19 January 2011
…created in 1991. For the first few years, the emphasis was on both price and quality competition; more recently, the focus has shifted to fixed prices, with competition based of…